Visit https://www.peervoice.com/TDK860 to view the entire programme with slides. After completing “Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT”, participants will be able to: Evaluate the burden and prevalence of CV disease in men with advanced prostate cancer; Differentiate between the impact of GnRH agonists and antagonists on CV risk; and Identify how future therapeutic strategies could evolve that reduce CV risk and which men would benefit most.